Our Lead Compound GF-1002

Genflow Biosciences' leading compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. This innovative therapy features a recombinant self-complementary AAV, carrying a transgene that encodes the cDNA for a variant of the human SIRT6 gene, which is associated with longevity in centenarians. Additionally, our product pipeline includes a variety of cutting-edge gene delivery solutions aimed at providing therapeutic benefits across several clinical conditions with significant unmet medical needs.